Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000096090

Apexbio Technology LLC LY3009120 1454682-72-4 25mg
SDP

Catalog No. 5000096090
Encompass_Preferred

LY3009120 (CAS 1454682-72-4) is a pan-RAF inhibitor that targets both monomeric and dimeric forms of RAF kinases including wild-type BRAF CRAF and mutant forms such as BRAFV600E and BRAFV600E G468A with IC50 values ranging from 5 8 to 17 nM By suppressing RAF activity LY3009120 disrupts downstream phosphorylation of MEK and ERK modulating MAPK/ERK signaling involved in cell proliferation and survival In cell models harboring NRAS or KRAS mutations as well as BRAF V600E mutant melanoma LY3009120 induces G0/G1 cell cycle arrest and minimizes paradoxical pathway activation In vivo it achieves dose-dependent inhibition of MEK and ERK phosphorylation and drives near-complete tumor regression in xenograft models LY3009120 is valuable for investigating RAF-mediated oncogenic processes and resistance mechanisms in MAPK-driven cancers

Catalog No. 50-000-96090 Supplier Apexbio Technology LLC Supplier No. A871625
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

LY3009120 (CAS 1454682-72-4) is a pan-RAF inhibitor that targets both monomeric and dimeric forms of RAF kinases including wild-type BRAF CRAF and mutant forms such as BRAFV600E and BRAFV600E G468A with IC50 values ranging from 5 8 to 17 nM By suppressing RAF activity LY3009120 disrupts downstream phosphorylation of MEK and ERK modulating MAPK/ERK signaling involved in cell proliferation and survival In cell models harboring NRAS or KRAS mutations as well as BRAF V600E mutant melanoma LY3009120 induces G0/G1 cell cycle arrest and minimizes paradoxical pathway activation In vivo it achieves dose-dependent inhibition of MEK and ERK phosphorylation and drives near-complete tumor regression in xenograft models LY3009120 is valuable for investigating RAF-mediated oncogenic processes and resistance mechanisms in MAPK-driven cancers

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.